Latest news
Subcutaneous Amivantamab Receives FDA Priority Review in R/M HNSCC - CancerNetworkCancerNetwork · Fri, 31 Jul 2026 17:08:12 GMTRybrevant Faspro Receives FDA Priority Review for Head and Neck Cancer - BioPharm InternationalBioPharm International · Thu, 30 Jul 2026 17:19:40 GMTJohnson & Johnson therapy shows 42% response in head and neck cancer - Stock TitanStock Titan · Thu, 30 Jul 2026 12:30:00 GMT